S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
Biden's Plan to Confiscate Your Cash? (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Boredom, loneliness plague Ukrainian youth near front line
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
Biden's Plan to Confiscate Your Cash? (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Boredom, loneliness plague Ukrainian youth near front line
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
Biden's Plan to Confiscate Your Cash? (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Boredom, loneliness plague Ukrainian youth near front line
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Is AMC Entertainment Pulling a Fast One on the APEs?
Biden's Plan to Confiscate Your Cash? (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Boredom, loneliness plague Ukrainian youth near front line
High oil prices help Saudi Aramco earn $88B in first half
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Ship carrying grain for hungry Ethiopia leaves Ukraine
Here’s How the Inflation Reduction Act Energizes Power Stock
Average US gasoline price falls 45 cents to $4.10 per gallon
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:BLPH

Bellerophon Therapeutics - BLPH Stock Forecast, Price & News

$1.42
+0.03 (+2.16%)
(As of 08/12/2022 09:14 PM ET)
Add
Compare
Today's Range
$1.39
$1.45
50-Day Range
$0.86
$1.69
52-Week Range
$0.67
$4.49
Volume
10,000 shs
Average Volume
51,736 shs
Market Capitalization
$13.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

Bellerophon Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,238.0% Upside
$19.00 Price Target
Short Interest
Healthy
0.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
1.07mentions of Bellerophon Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.31) to ($1.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

155th out of 1,135 stocks

Pharmaceutical Preparations Industry

65th out of 557 stocks

BLPH stock logo

About Bellerophon Therapeutics (NASDAQ:BLPH) Stock

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Bellerophon Therapeutics Stock Up 2.2 %

BLPH Stock traded up $0.03 during midday trading on Friday, reaching $1.42. The company had a trading volume of 10,040 shares, compared to its average volume of 20,722. The company has a 50 day moving average of $1.23 and a two-hundred day moving average of $1.63. Bellerophon Therapeutics has a 1 year low of $0.67 and a 1 year high of $4.49.

Bellerophon Therapeutics (NASDAQ:BLPH - Get Rating) last announced its quarterly earnings data on Wednesday, May 11th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, equities analysts anticipate that Bellerophon Therapeutics will post -2.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Bellerophon Therapeutics in a research note on Tuesday, August 9th. They issued a "sell" rating for the company.

Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Stock News Headlines

See More Headlines
Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BLPH Company Calendar

Last Earnings
11/15/2021
Today
8/15/2022
Next Earnings (Estimated)
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLPH
Fax
N/A
Employees
21
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+1,238.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-17,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.27 per share

Miscellaneous

Free Float
7,187,000
Market Cap
$13.55 million
Optionable
Not Optionable
Beta
-0.12

Key Executives

  • Mr. Peter Fernandes M. Pharm (Age 67)
    Principal Exec. Officer and Chief Regulatory, Safety & Quality Officer
    Comp: $478.84k
  • Dr. Parag Suresh Shah (Age 45)
    VP of Bus. Operations
    Comp: $377.9k
  • Mr. Nicholas Laccona (Age 33)
    Principal Financial & Accounting Officer and Sec.
  • Dr. Edwin L. Parsley (Age 61)
    Acting Chief Medical Officer













BLPH Stock - Frequently Asked Questions

Should I buy or sell Bellerophon Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLPH shares.
View BLPH analyst ratings
or view top-rated stocks.

What is Bellerophon Therapeutics' stock price forecast for 2022?

1 analysts have issued 1 year target prices for Bellerophon Therapeutics' shares. Their BLPH share price forecasts range from $19.00 to $19.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 1,238.0% from the stock's current price.
View analysts price targets for BLPH
or view top-rated stocks among Wall Street analysts.

How have BLPH shares performed in 2022?

Bellerophon Therapeutics' stock was trading at $3.10 at the beginning of 2022. Since then, BLPH shares have decreased by 54.2% and is now trading at $1.42.
View the best growth stocks for 2022 here
.

When is Bellerophon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 18th 2022.
View our BLPH earnings forecast
.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) announced its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.14.

When did Bellerophon Therapeutics' stock split?

Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.19%) and Sepio Capital LP (0.25%). Insiders that own company stock include Associates Iv L P Venrock, New Mountain Investments Ii, L, Theodore T Wang and Wassim Fares.
View institutional ownership trends
.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $1.42.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $13.55 million. The biotechnology company earns $-17,760,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.

This page (NASDAQ:BLPH) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.